CG Oncology (CGON) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CG Oncology (CGON) has outperformed Vaxcyte (PCVX) over the past year, gaining 87.3% versus a gain of 15.9%. Vaxcyte is the larger company by market cap ($8.77 billion vs $7.10 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | PCVX |
|---|---|---|
| Share price | $79.47 | $55.39 |
| Market cap | $7.10B | $8.77B |
| 1-day change | -2.97% | -5.09% |
| YTD return | +91.40% | +20.05% |
| 1-year return | +87.25% | +15.93% |
| 5-year return | — | +178.90% |
| EPS (TTM) | $-2.76 | $-8.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | — |
| Revenue growth (YoY) | +254.70% | — |
| Net income (latest FY) | $-161.00M | $-766.63M |
| Operating margin | -4722.13% | — |
| Net margin | -3985.02% | — |
| 52-week high | $93.95 | $90.75 |
| 52-week low | $37.01 | $42.40 |
| Distance from 52-week high | -15.41% | -38.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +38.03% | +110.15% |
| Average volume | 1.24M | 2.19M |
| Shares outstanding | 89.32M | 158.30M |
| Employees | 142 | 507 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGON has outperformed PCVX by 71.3 percentage points over the past year.
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
CGON vs PCVX FAQ
Which is bigger, CG Oncology or Vaxcyte?
Vaxcyte (PCVX) is larger, with a market capitalization of $8.77B compared with $7.10B for CG Oncology (CGON).
Which stock has performed better over the past year, CGON or PCVX?
CGON returned +87.25% over the past 12 months, compared with +15.93% for PCVX (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.